COMMUNIQUÉS West-GlobeNewswire

Evaxion annonce le succès des phases initiales de sa collaboration actuelle avec MSD dans le domaine des vaccins

21/02/2024 - 12:27

COPENHAGUE, Danemark, 21 févr. 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie axée sur la recherche clinique spécialisée dans le développement [...]

Turnstone Biologics to Participate in Upcoming Investor Conferences

21/02/2024 - 12:00

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure [...]

Immuron Presentation Australian Biologics Festival 2024

21/02/2024 - 12:00

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development [...]

Introducing LQpay’s R2B2 - The Next Generation “Zero-Click Payment Solution,” Broadening Access for Dental Practices

21/02/2024 - 11:25

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- LQpay , a leader in innovative healthcare payments solutions, is proud to announce the launch of “R2B2,” the next generation of its exclusive Zero-Click Payment [...]

Inside information - BBS-Bioactive Bone Substitutes Plc: Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and RiverFort to strengthen the working capital position

21/02/2024 - 09:30

BBS-Bioactive Bone Substitutes Plc, Company announcement, inside information, 21 February 2024 at 10:30 am EET Drawdown of an advance pursuant to financing arrangement between BBS-Bioactive Bone Substitutes Plc and [...]

Bavarian Nordic delivered record financial results in 2023

21/02/2024 - 08:13

Preliminary 2023 results exceed the latest guidance and represent the best-ever financial result in the Company’s history driven by extraordinary growth in travel health and a surge in smallpox/mpox vaccine sales. 2024 [...]

EssilorLuxottica and Michael Kors Announce Extended Licensing Partnership

21/02/2024 - 07:00

EssilorLuxottica and Michael Kors Announce Extended Licensing Partnership Charenton-le-Pont, France, and New York, US (February, 21 2024 – 07:00 am CET) - EssilorLuxottica and Michael Kors announced today the renewal of [...]

EssilorLuxottica et Michael Kors étendent leur accord de licence

21/02/2024 - 07:00

EssilorLuxottica et Michael Kors étendent leur accord de licence Charenton-le-Pont, France et New York, Etats-Unis (21 février 2024 – 07h00) - EssilorLuxottica et Michael Kors annoncent le renouvellement de leur accord [...]

PolTREG appoints Dan Shelly as Chief Business Development Officer

21/02/2024 - 07:00

Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune diseases, announces today it has appointed [...]

Sienna Senior Living Inc. Reports Strong Fourth Quarter 2023 Financial Results and Delivers 16.5% Increase in Same Property Net Operating Income

21/02/2024 - 00:15

MARKHAM, Ontario, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced its financial results for the three months and year ended December 31, 2023. The [...]

Sanofi: Information concerning the total number of voting rights and shares - January 2024

20/02/2024 - 23:41

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Janvier 2024

20/02/2024 - 23:41

Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

20/02/2024 - 23:00

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure [...]

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

20/02/2024 - 23:00

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients [...]

Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024

20/02/2024 - 22:36

LOWELL, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate [...]

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

20/02/2024 - 22:30

Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceutical company focused [...]

DBV Technologies participera au prochain congrès de l’AAAAI 2024

20/02/2024 - 22:30

Montrouge, France, le 20 février 2024 DBV Technologies participera au prochain congrès de l’AAAAI 2024 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – NASDAQ : DBVT), une entreprise biopharmaceutique au stade [...]

Viemed Healthcare Announces Date and Time for Conference Call

20/02/2024 - 22:30

LAFAYETTE, La., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “ Company ” or “ Viemed ”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, [...]

GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024

20/02/2024 - 22:26

Reported fourth quarter 2023 revenue from continuing operations 1 of $58.1M with more than 68% year-over-year growth of exome and genome test revenue Expanded fourth quarter 2023 adjusted gross margins 2 from continuing [...]